An open label single center pilot study investigating the clinical response and mechanism of action of infliximab in the treatment of adults with inflammatory bowel disease who have moderate to severe pyoderma gangrenosum

Trial Profile

An open label single center pilot study investigating the clinical response and mechanism of action of infliximab in the treatment of adults with inflammatory bowel disease who have moderate to severe pyoderma gangrenosum

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Pyoderma gangrenosum; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jun 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 15 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top